KDR and colorectal carcinoma: Inhibitors of the vascular endothelial growth factor receptors (VEGFR) such as fruquitinib, trifluridine/tipiracil (FTD/TPI), and the monoclonal antibody (bevacizumab) have proven efficacious in the treatment of CRC cells that were previously resistant to available chemotherapies.